Role of Vascular Endothelial Growth Factor in Ovarian Cancer: Inhibition of Ascites Formation by Immunoneutralization

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 1998 Oct 20

PMID 9777956

Citations 93

Authors

S Mesiano

N Ferrara

R B Jaffe

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is characterized by the rapid growth of solid intraperitoneal tumors and large volumes of ascitic fluid. Vascular endothelial growth factor (VEGF) augments tumor growth by inducing neovascularization and may stimulate ascites formation by increasing vascular permeability. We examined the role of VEGF in ovarian carcinoma using in vivo models in which intraperitoneal or subcutaneous tumors were induced in immunodeficient mice using the human ovarian carcinoma cell line SKOV-3. After tumor engraftment (7 to 10 days), some mice were treated with a function-blocking VEGF antibody (A4.6.1) specific for human VEGF. A4.6.1 significantly (P < 0.05) inhibited subcutaneous SKOV-3 tumor growth compared with controls. However, tumor growth resumed when A4.6.1 treatment was discontinued. In mice bearing intraperitoneal tumors (IP mice), ascites production and intraperitoneal carcinomatosis were detected 3 to 7 weeks after SKOV-3 inoculation. Importantly, A4.6.1 completely inhibited ascites production in IP mice, although it only partially inhibited intraperitoneal tumor growth. Tumor burden was variable in A4.6.1-treated IP mice; some had minimal tumor, whereas in others tumor burden was similar to that of controls. When A4.6.1 treatment was stopped, IP mice rapidly (within 2 weeks) developed ascites and became cachectic. These data suggest that in ovarian cancer, tumor-derived VEGF is obligatory for ascites formation but not for intraperitoneal tumor growth. Neutralization of VEGF activity may have clinical application in inhibiting malignant ascites formation in ovarian cancer.

Citing Articles

Bevacizumab combined with platinum-based chemotherapy in primary or relapsed ovarian cancer patients: Meta-analysis and literature to review.

Tauseef A, Zafar M, Abodunrin F, Siddiqui S, Millner P, Khan S J Family Med Prim Care. 2024; 12(11):2797-2804.

PMID: 38186770 PMC: 10771148. DOI: 10.4103/jfmpc.jfmpc_2140_22.

Mechanism of ozone alleviation of malignant ascites in hepatocellular carcinoma through the inhibition of neutrophil extracellular traps.

Han F, Guo J, Mu M, Bian K, Cui Z, Duan Q PNAS Nexus. 2023; 2(9):pgad280.

PMID: 37693209 PMC: 10485884. DOI: 10.1093/pnasnexus/pgad280.

Lymphatic vasculature in ovarian cancer.

Pal S, Bhowmick S, Sharma A, Sierra-Fonseca J, Mondal S, Afolabi F Biochim Biophys Acta Rev Cancer. 2023; 1878(5):188950.

PMID: 37419192 PMC: 10754213. DOI: 10.1016/j.bbcan.2023.188950.

Therapeutic implications of the tumor microenvironment in ovarian cancer patients receiving PD-1/PD-L1 therapy.

Wang Y, Zhang L, Bai Y, Wang L, Ma X Front Immunol. 2022; 13:1036298.

PMID: 36341388 PMC: 9630909. DOI: 10.3389/fimmu.2022.1036298.

Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8-unrelated effusion large B-cell lymphoma in vivo.

Ogasawara F, Higuchi T, Nishimori T, Hashida Y, Kojima K, Daibata M J Cell Mol Med. 2022; 26(22):5580-5589.

PMID: 36209502 PMC: 9667516. DOI: 10.1111/jcmm.17570.

References

Terman B, Carrion M, Kovacs E, Rasmussen B, Eddy R, Shows T . Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene. 1991; 6(9):1677-83. View

Dvorak H, Sioussat T, Brown L, Berse B, Nagy J, Sotrel A . Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med. 1991; 174(5):1275-8. PMC: 2118980. DOI: 10.1084/jem.174.5.1275. View

Berse B, Brown L, Van de Water L, Dvorak H, Senger D . Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell. 1992; 3(2):211-20. PMC: 275520. DOI: 10.1091/mbc.3.2.211. View

Ferrara N, Houck K, Jakeman L, Leung D . Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992; 13(1):18-32. DOI: 10.1210/edrv-13-1-18. View

Weindel K, Marme D, Weich H . AIDS-associated Kaposi's sarcoma cells in culture express vascular endothelial growth factor. Biochem Biophys Res Commun. 1992; 183(3):1167-74. DOI: 10.1016/s0006-291x(05)80313-4. View

Macchiarini P, Fontanini G, Hardin M, SQUARTINI F, Angeletti C . Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 1992; 340(8812):145-6. DOI: 10.1016/0140-6736(92)93217-b. View

Alvarez J, Baird A, Tatum A, Daucher J, Chorsky R, Gonzalez A . Localization of basic fibroblast growth factor and vascular endothelial growth factor in human glial neoplasms. Mod Pathol. 1992; 5(3):303-7. View

Kim K, Li B, Houck K, Winer J, Ferrara N . The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992; 7(1):53-64. DOI: 10.3109/08977199209023937. View

Plate K, Breier G, Weich H, Risau W . Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992; 359(6398):845-8. DOI: 10.1038/359845a0. View

10.

Kutteh W, Kutteh C . Quantitation of tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in the effusions of ovarian epithelial neoplasms. Am J Obstet Gynecol. 1992; 167(6):1864-9. DOI: 10.1016/0002-9378(92)91788-c. View

11.

Sioussat T, Dvorak H, Brock T, Senger D . Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Arch Biochem Biophys. 1993; 301(1):15-20. DOI: 10.1006/abbi.1993.1109. View

12.

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

13.

Yeo K, Wang H, Nagy J, Sioussat T, Ledbetter S, Hoogewerf A . Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res. 1993; 53(12):2912-8. View

14.

Weidner N, Carroll P, Flax J, BLUMENFELD W, Folkman J . Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993; 143(2):401-9. PMC: 1887042. View

15.

Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K . Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 1993; 53(19):4550-4. View

16.

Brown L, Berse B, Jackman R, Tognazzi K, Manseau E, Senger D . Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 1993; 53(19):4727-35. View

17.

Brown L, Berse B, Jackman R, Tognazzi K, Manseau E, Dvorak H . Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993; 143(5):1255-62. PMC: 1887185. View

18.

Olson T, Mohanraj D, Carson L, Ramakrishnan S . Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 1994; 54(1):276-80. View

19.

Di Blasio A, Cremonesi L, Vigano P, Ferrari M, GOSPODAROWICZ D, Vignali M . Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms. Am J Obstet Gynecol. 1993; 169(6):1517-23. DOI: 10.1016/0002-9378(93)90428-l. View

20.

Senger D, Van de Water L, Brown L, Nagy J, Yeo K, Yeo T . Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993; 12(3-4):303-24. DOI: 10.1007/BF00665960. View